Hepta, a liquid biopsy company, has announced that its blood test significantly outperforms traditional non-invasive tests such as FIB-4, ELF, and FibroScan in identifying patients with metabolic dysfunction-associated steatohepatitis (MASH) who are eligible for treatment. The clinical data, derived from a study involving 528 biopsy-confirmed MASH patients, will be presented at the European Association for the Study of the Liver (EASL) 2026 Congress. The results indicate that Hepta's test, which utilizes cfDNA methylation analysis, achieved an area under the curve (AUC) of 0.83 in detecting significant fibrosis (F2+). This performance is crucial as existing tests often miss nearly one-third of patients who qualify for therapy. Hepta's LiquidTransformer platform, an AI model trained on extensive data, allows for a non-invasive approach to accurately assess disease biology, facilitating better treatment decisions. The findings underscore the potential for Hepta's blood test to transform the management of MASH, providing clinicians with a reliable tool to identify and monitor treatment-eligible patients effectively.